Ask AI
ProCE Banner Activity

Global Guide to First-line Treatment for CLL/SLL

Slideset

Download these slides for the latest evidence and recommendations to guide BTK inhibitor treatment decisions and adverse event management in patients with newly diagnosed chronic lymphocytic leukemia.

Released: February 10, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematologists, medical oncologists and other healthcare professionals involved in the treatment of patients with CLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess approved frontline BTK inhibitors considering binding, targeted selectivity, global indications, dosing, safety profile, and efficacy

  • Develop individualized, BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL that reflect current clinical trial data, expert insights, and evolving global treatment recommendations, including considerations for both continuous and fixed-duration regimens

  • Apply evidence-based guideline-directed clinical strategies to manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation for optimal patient outcomes